IDH mutation testing in gliomas-where do we draw the line?

Neuro Oncol. 2017 Nov 29;19(12):1568-1569. doi: 10.1093/neuonc/nox164.
No abstract available

Publication types

  • Kommentar

MeSH terms

  • Cost-Benefit Analysis
  • Glioma*
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Mutation
  • Nervous System

Substances

  • Isocitrate Dehydrogenase